Radiotherapy combined with cetuximab for locally advanced head and neck cancer: Results and toxicity

Acevedo-Henao, C.M.; Valette, G.; Miglierini, P.; Lefur, Eloise; Pradier, Olivier

doi:10.1016/j.canrad.2012.06.005

Cited by 21 publications

(17 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Radiation is known to induce EGFR signaling, possibly resulting in upregulation of vascular endothelial growth factor, stimulating growth of poorly differentiated vessels (35)(36)(37)(38). However, we found no correlation between the increased perfusion and increase in uptake of 111 Incetuximab-F(ab9) 2 . SCCNij167 did not show a similar increase in 111 In-cetuximab-F(ab9) 2 uptake in treated tumors, and overall uptake remained low.…”

Section: Discussioncontrasting

confidence: 50%

“…Cetuximab-resistant SCCNij167 did not show an increased uptake of 111 In-cetuximab-F(ab9) 2 after irradiation. These findings suggest that 111 In-cetuximab-F(ab9) 2 can be used to measure radiation-induced changes of EGFR expression and thus could monitor the compensatory response of tumors to radiation treatment and potentially aid in EGFR inhibitor response prediction.…”

Section: Resultsmentioning

confidence: 99%

“…We have shown that the change in EGFR accessibility induced by irradiation can be visualized with 111 In-cetuximab-F(ab9) 2 . The cetuximab-responsive SCCNij202 showed a significant increase in tracer uptake, possibly related to the translocation of cytoplasmatic EGFR to the cell membrane.…”

Section: Resultsmentioning

confidence: 99%

“…In this study, we evaluated whether 111 In-cetuximab-F(ab9) 2 SPECT could visualize and monitor EGFR modulation after irradiation, using a cetuximab-sensitive and cetuximab-resistant HNSCC mouse model. Additionally, we evaluated the application of 18 F-FDG PET to monitor the effect of irradiation.…”

Section: Discussionmentioning

confidence: 99%

“…In previous work, a preclinical SPECT tracer, 111 In-cetuximab-F(ab9) 2 , which can visualize the EGFR in HNSCC xenografts, was developed (22,23). Of these xenografts, responsiveness was evaluated designating SCCNij202 as sensitive and SCCNij167 as resistant, showing high tracer versus low tracer uptake, respectively (14).…”

mentioning

confidence: 99%

See 4 more Smart Citations

Early Response Monitoring with ¹⁸F-FDG PET and Cetuximab-F(ab′)₂-SPECT After Radiotherapy of Human Head and Neck Squamous Cell Carcinomas in a Mouse Model

et al. 2014

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 50%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Early Response Monitoring with ¹⁸F-FDG PET and Cetuximab-F(ab′)₂-SPECT After Radiotherapy of Human Head and Neck Squamous Cell Carcinomas in a Mouse Model

et al. 2014

View full text Add to dashboard Cite

Improvement in survival of patients with oral cavity squamous cell carcinoma: An international collaborative study

Amit

Yen

Liao

et al. 2013

Cancer

146

122

View full text Add to dashboard Cite

BACKGROUND An association between the survival of patients with oral cavity squamous cell carcinoma (OCSCC) and advancements in diagnosis and therapy has not been established. METHODS This was a retrospective, longitudinal, international, population‐based study of 2738 patients who underwent resection of OCSCC during 2 different decades. Characteristics of patients from 7 international cancer centers who received treatment between 1990 and 2000 (group A; n = 735) were compared with patients who received treatment between 2001 and 2011 (group B; n = 2003). RESULTS Patients in group B had more advanced tumors and tended to develop distant metastases more frequently than patients in group A (P = .005). More group B patients underwent selective neck dissection and received adjuvant radiotherapy (P < .001). Outcome analysis revealed a significant improvement in 5‐year overall survival, from 59% for group A to 70% for group B (P < .001). There was also a significant improvement in disease‐specific survival associated with operations performed before and after 2000 (from 69% to 81%, respectively; P < .001). Surgery after 2000, negative margins, adjuvant treatment, and early stage disease were independent predictors of a better outcome in multivariate analysis. The decade of treatment was an independent prognostic factor for cancer‐specific mortality (hazard ratio, 0.42; 95% confidence interval, 0.3‐0.6). CONCLUSIONS The survival rate of patients with OCSCC improved significantly during the past 2 decades despite older age, more advanced disease stage, and a higher rate of distant metastases. The current results suggest that the prognosis for patients with OCSCC has improved over time, presumably because of advances in imaging and therapy. Cancer 2013;119:4242–4248. © 2013 American Cancer Society.

show abstract

Evaluation of 18F‐FDG PET/CT as an early imaging biomarker for response monitoring after radiochemotherapy using cetuximab in head and heck squamous cell carcinoma

et al. 2019

View full text Add to dashboard Cite

Background: To determine whether 18 F-PET/CT is able to identify treatment response as early as 1 week after the end of chemoradiotherapy, whether 18 F-PET/ CT can identify prognostic markers concerning progression free survival and can identify patients who need additional consolidation therapy. Methods: A total of 54 patients with head and neck cancer were prospectively enrolled in this single-center, randomized study from 03/2012-04/2015. Patients underwent FDG-PET/CT imaging at three predefined time points: pretreatment (PET/CT1), 1 week postprimary radiochemotherapy (PET/CT2) and 3 months postprimary radiochemotherapy (PET/CT3). Tumors were assessed quantitatively based on size and glucose uptake (SUVmax) concerning response at each time point. Response assessment was correlated with progression free survival. All patients had a minimum follow-up period of 18 months. Multivariate regression analysis was performed to find independent predictors for progression free survival (PFS). Results: Thirty-two (32) patients (64%) overall remained disease free, 11 patients (22%) had recurrence and 7 patients (14%) had persistent disease. There was no significantly different metabolic parameter ratio found concerning responders and nonresponders at posttreatment (PET/CT2 and 3) time points (P > .05) during clinical follow-up. Multivariate regression analysis demonstrated both SUVmax and diameter assessed at time point PET/CT3 represent independent predictors of progression free survival (PFS). There was also no statistically significant difference in PFS between responders and nonresponders by means of PET/CT2 in both study arms (P > .05). Imaging responders at time point PET/CT3 showed a significantly longer PFS compared to nonresponders after the end of consolidation therapy (P < .01). Conclusions: Early response of head/neck cancer after radiochemotherapy can be accurately assessed with PET/CT 1 week after RCT. SUVmax and lesion diameter are independent predictors of PFS at time point PET/CT3. PET/CT2 has no

show abstract

Radiotherapy combined with cetuximab for locally advanced head and neck cancer: Results and toxicity

Cited by 21 publications

References 10 publications

Early Response Monitoring with ¹⁸F-FDG PET and Cetuximab-F(ab′)₂-SPECT After Radiotherapy of Human Head and Neck Squamous Cell Carcinomas in a Mouse Model

Early Response Monitoring with ¹⁸F-FDG PET and Cetuximab-F(ab′)₂-SPECT After Radiotherapy of Human Head and Neck Squamous Cell Carcinomas in a Mouse Model

Improvement in survival of patients with oral cavity squamous cell carcinoma: An international collaborative study

Evaluation of 18F‐FDG PET/CT as an early imaging biomarker for response monitoring after radiochemotherapy using cetuximab in head and heck squamous cell carcinoma

Contact Info

Product

Resources

About

Radiotherapy combined with cetuximab for locally advanced head and neck cancer: Results and toxicity

Cited by 21 publications

References 10 publications

Early Response Monitoring with 18F-FDG PET and Cetuximab-F(ab′)2-SPECT After Radiotherapy of Human Head and Neck Squamous Cell Carcinomas in a Mouse Model

Early Response Monitoring with 18F-FDG PET and Cetuximab-F(ab′)2-SPECT After Radiotherapy of Human Head and Neck Squamous Cell Carcinomas in a Mouse Model

Improvement in survival of patients with oral cavity squamous cell carcinoma: An international collaborative study

Evaluation of 18F‐FDG PET/CT as an early imaging biomarker for response monitoring after radiochemotherapy using cetuximab in head and heck squamous cell carcinoma

Contact Info

Product

Resources

About

Early Response Monitoring with ¹⁸F-FDG PET and Cetuximab-F(ab′)₂-SPECT After Radiotherapy of Human Head and Neck Squamous Cell Carcinomas in a Mouse Model

Early Response Monitoring with ¹⁸F-FDG PET and Cetuximab-F(ab′)₂-SPECT After Radiotherapy of Human Head and Neck Squamous Cell Carcinomas in a Mouse Model